1. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial. Issue 8 (August 2019) Authors: Herbst, Roy S; Arkenau, Hendrik-Tobias; Santana-Davila, Rafael; Calvo, Emiliano; Paz-Ares, Luis; Cassier, Philippe A; Bendell, Johanna; Penel, Nicolas; Krebs, Matthew G; Martin-Liberal, Juan; Isambert, Nicolas; Soriano, Andres; Wermke, Martin; Cultrera, Jennifer; Gao, Ling; Widau, Ryan C; Mi, Gu;... Journal: Lancet oncology Issue: Volume 20:Issue 8(2019) Page Start: 1109 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial. Issue 11 (November 2019) Authors: Naing, Aung; Wong, Deborah J; Infante, Jeffrey R; Korn, W Michael; Aljumaily, Raid; Papadopoulos, Kyriakos P; Autio, Karen A; Pant, Shubham; Bauer, Todd M; Drakaki, Alexandra; Daver, Naval G; Hung, Annie; Ratti, Navneet; McCauley, Scott; Van Vlasselaer, Peter; Verma, Rakesh; Ferry, David; Oft, Ma... Journal: Lancet oncology Issue: Volume 20:Issue 11(2019) Page Start: 1544 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial. Issue 3 (March 2019) Authors: Luft, Alexander V.; Karaseva, Nina A.; Kowalyszyn, Rubén Dario; Hernandez, Carlos Alberto; Csoszi, Tibor; De Vita, Ferdinando; Pfeiffer, Per; Sugimoto, Naotoshi; Kocsis, Judit; Csilla, Andràs; Bodoky, Gyorgy; Garnica Jaliffe, Georgina; Protsenko, Svetlana; Madi, Ayman; Wojcik, Elzbieta; Brenner, ... Journal: Lancet oncology Issue: Volume 20:Issue 3(2019) Page Start: 420 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open‐Label, Phase I Trial (JVDF). (31st May 2018) Authors: Arkenau, Hendrik‐Tobias; Martin‐Liberal, Juan; Calvo, Emiliano; Penel, Nicolas; Krebs, Matthew G.; Herbst, Roy S.; Walgren, Richard A.; Widau, Ryan C.; Mi, Gu; Jin, Jin; Ferry, David; Chau, Ian Journal: Oncologist Issue: Volume 23:Number 12(2018) Page Start: 1407 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Electrocardiographic Characterization of Ramucirumab on the Corrected QT Interval in a Phase II Study of Patients With Advanced Solid Tumors. (16th March 2016) Authors: Olszanski, Anthony J.; Smith, David C.; Camacho, Luis H.; Thompson, John; Ramalingam, Suresh S.; Harvey, R. Donald; Campos, Luis; Ferry, David; Tang, Shande; Gao, Ling; Safran, Howard Journal: Oncologist Issue: Volume 21:Number 4(2016) Page Start: 402 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Pegilodecakin as monotherapy or in combination with anti‐PD‐1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma: Final results of cohorts A, G, H and I of IVY Phase I study. Issue 2 (24th March 2021) Authors: Tannir, Nizar M.; Papadopoulos, Kyriakos P.; Wong, Deborah J.; Aljumaily, Raid; Hung, Annie; Afable, Manuel; Kim, Jong Seok; Ferry, David; Drakaki, Alexandra; Bendell, Johanna; Naing, Aung Journal: International journal of cancer Issue: Volume 149:Issue 2(2021) Page Start: 403 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial. Issue 9 (September 2022) Authors: Lu, Shun; Wu, Lin; Jian, Hong; Chen, Ying; Wang, Qiming; Fang, Jian; Wang, Ziping; Hu, Yanping; Sun, Meili; Han, Liang; Miao, Liyun; Ding, Cuimin; Cui, Jiuwei; Li, Baolan; Pan, Yueyin; Li, Xingya; Ye, Feng; Liu, Anwen; Wang, Ke; Cang, Shundong Journal: Lancet oncology Issue: Volume 23:Issue 9(2022) Page Start: 1167 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Residual breast tissue after robot-assisted nipple sparing mastectomy. (February 2021) Authors: Park, Ko Un; Tozbikian, Gary H.; Ferry, David; Tsung, Allan; Chetta, Mathew; Schulz, Steven; Skoracki, Roman Journal: Breast Issue: Volume 55(2021) Page Start: 25 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. On Translating Virgil: A Response. (28th January 2021) Authors: Ferry, David Journal: Essays in criticism Issue: Volume 71:Number 1(2021) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Comment on: Risk of gastrointestinal perforation in cancer patients receiving ramucirumab: a meta-analysis of randomized controlled trials. (2nd January 2017) Authors: Sashegyi, Andreas; Zhang, Yawei; Lin, Yong; Binder, Polina; Ferry, David Journal: Journal of chemotherapy Issue: Volume 29:Number 1(2017) Page Start: 62 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗